Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Instagram Outage Disrupts Thousands of U.S. Users 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2017 -- G1 Therapeutics, Inc., a clinical-stage oncology company, announced today that Chief Executive Officer Mark Velleca, MD, PhD, will present a company overview at the 35th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Tuesday, January 10, at 9 a.m. PT at The Westin St. Francis Hotel in San Francisco.
About G1 Therapeutics, Inc.
G1 Therapeutics is a clinical-stage oncology company developing novel, small-molecule therapies that address significant unmet needs in people with cancer. The company is advancing a pipeline of potential best-in-class and first-in-class drug candidates in multiple oncology indications. G1 is privately held and based in Research Triangle Park, NC.
Visit www.g1therapeutics.com for more information.
Contact: Mark Velleca, MD, PhD G1 Therapeutics 919-213-9838 [email protected] Investors: Robert Uhl Westwicke Partners 858-356-5932 [email protected] Media: Laura Bagby 6 Degrees Communications 312-448-8098 [email protected]
